US20090291020A1 - Soft contact lens solution containing hyaluronic acid - Google Patents

Soft contact lens solution containing hyaluronic acid Download PDF

Info

Publication number
US20090291020A1
US20090291020A1 US12/512,521 US51252109A US2009291020A1 US 20090291020 A1 US20090291020 A1 US 20090291020A1 US 51252109 A US51252109 A US 51252109A US 2009291020 A1 US2009291020 A1 US 2009291020A1
Authority
US
United States
Prior art keywords
contact lens
solution
soft contact
eye
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/512,521
Inventor
Louis Johan Wagenaar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19772702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20090291020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US12/512,521 priority Critical patent/US20090291020A1/en
Publication of US20090291020A1 publication Critical patent/US20090291020A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/0005Other compounding ingredients characterised by their effect
    • C11D3/0078Compositions for cleaning contact lenses, spectacles or lenses

Definitions

  • the current invention provides a procedure for the manufacture of contact lenses for eye treatment, eye protection and/or eye-care.
  • the invention also provides a composition for the impregnation of a contact lens for the treatment and/or care and/or protection of the eye, a kit containing such a composition and one or more contact lenses as well as contact lenses impregnated with the composition.
  • contact lens wearers may need extra protection for their eyes. It could be useful to the eyes to dispense extra nutrition, such as vitamins and provitamins or, additionally, those substances which offer protection or allow, support or accelerate the repair of an occurring damage.
  • extra nutrition such as vitamins and provitamins or, additionally, those substances which offer protection or allow, support or accelerate the repair of an occurring damage.
  • eye healthcare several products are known to assist in the accelerated recovery of the soundness of the cornea. These products, however, usually have to be administered (dripped in or applied onto the eye) separately or have to be swallowed by the user.
  • a method for the production of contact lenses for the treatment and/or care and/or protection of the eye may comprise the impregnation of contact lenses in a solution which comprises one or more suitable components for the treatment and/or care and/or protection of the eye.
  • composition for the treatment and/or care and/or protection of the eye may comprise at least one suitable component for the treatment and/or care and/or protection of the eye.
  • a contact lens for treatment and/or care and/or protection of the eye may be impregnated with a composition comprising at least one suitable component for the treatment and/or care and/or protection of the eye.
  • the current invention therefore provides a method for the manufacture of contact lenses for the treatment and/or care and/or protection of the eyes, comprising the impregnation of contact lenses in a solution which contains suitable compounds for the treatment and/or care and/or protection of the eyes.
  • a solution which contains suitable compounds for the treatment and/or care and/or protection of the eyes.
  • the current invention provides a composition for the impregnation of contact lenses for the treatment and/or care and/or protection of the eyes, comprising compounds suitable for eye treatment or care or protection.
  • the current invention offers various types of compounds dependent on the type of treatment, care or protection required.
  • these compositions can be combined with the compounds usually used for disinfecting, cleaning, insertion, moisturizing, rinsing or storing of contact lenses, so that the user need not add these compounds separately.
  • Compounds that can be applied are: for instance dexpanthenol, pantothenic acid, hyaluron acid, retinol (Vitamin A) and retinyl derivatives, carotene, thiamine (Vitamin B1), riboflavine (Vitamin B2), pyridoxine (Vitamin B6), nicotinic acid, nicotine acidamin, biotine (Vitamin B7), niacinamide and niacine (vitamin ⁇ B3), ascorbic acid (Vitamin C) and other anti-oxidants, saccharose, honey and other bee products, red beetroot syrup, collagen, gelatin, taurin, serine protease and other enzymes, propamidines, Vitamin D and its derivatives such as calciferol, Vitamin K
  • Products used for maintenance and storage of contact lenses like cleaning products and disinfecting solutions, and sprays, so-called all-in-one solutions, storage liquids and rinsing liquids, insertion solutions and moisturizers, neutralizers in either liquid or tablet form, gels, coatings and tablets which either make or assist in making contact lens solutions or make solutions come into being or are used for or in such solutions.
  • the composition can therefore appear in various forms, such as a solution, spray or tablet which after dissolution makes a solution.
  • Compounds intended for the care of contact lenses may also be part of a tablet which is combined with a solution that contains the care, treatment or protection agent or the reverse. Obviously both could also be included in one tablet or in separate tablets. Even so compounds can be included in a solution that is to be mixed with a solution without a compound.
  • An additional aim of the current invention is to disclose a method for improvement of the way a desired (and often necessary) antibacterial effect of a composition for contact lens care or eye-care/eye-drops can be reached.
  • a number of peptides are naturally found in the eye. They have a protective effect on the eye and particularly the cornea.
  • peptides can be used separately or in combination with other eye-care products or treatments.
  • composition according to the current invention can be applied when impregnating all kinds of contact lenses, especially and preferably soft lenses, but also hard lenses, disposable lenses and long-lasting ones as well as extended wear lenses and intra-ocular lenses would benefit. Impregnation can be carried out by the user, for instance during maintenance, but also, as with new lenses, in the delivery packaging.
  • a contact lens with this compound could be used when the user expects an allergic reaction, for example in a period with high levels of pollen.
  • Other compounds can be used as well to either prevent or reduce allergic reactions, such as emedastine, azelastine and nedocromil.
  • contact lenses according to the current invention could be found in the treatment of so-called “dry eyes” or irritated or red eyes, hence called “dry eyes.”
  • dry eyes or irritated or red eyes
  • eye-drops are used to treat this.
  • eye-drops usually offer only short-term relief.
  • the contact lenses according to the current invention offer a simple, cheap and elegant alternative.
  • the compounds suggested in the current invention could be particularly advantageous to use the compounds suggested in the current invention as giving relief to dry eyes in combination with polymers from which is known or believed that they, when used in eye-drops, offer relief, such as polymers of the type polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), hydroxy propyl cellulose (HPC), Carbomere or Dextrane.
  • PVP polyvinylpyrrolidone
  • PVA polyvinyl alcohol
  • HPMC hydroxypropyl methylcellulose
  • HPC hydroxy propyl cellulose
  • Carbomere or Dextrane Carbomere or Dextrane.
  • Other substances that may be combined with the compounds include polyhexamethylene biguanide hydrochloride (PHMB HCl), boric acid, borax, sodium chloride (NaCl), and ethylenediamine tetraacetic acid (EDTA).
  • contact lenses according to the current invention can also be used to apply substances which cure or correct eye-diseases or disorders and which should be administered once or several times a day to take sufficient effect at least part of the day.
  • the use of contact lenses according to the current invention could be effective here.
  • the use of contact lenses will generally result in a more constant level of the effective agent at the point of application than would have been possible with the use of eye-drops or even eye-balm.
  • Eye-balm also has the disadvantages of causing limited eyesight directly after application and a less easy way of application for some users compared to applying contact lenses.
  • the use of the current invention with their own lenses is particularly economical, because they do not need to perform any supplementary actions.
  • An advantage of the current invention is that the price of contact lenses has dropped considerably over the last few years especially that of short-term use lenses such as the so-called day-lenses, week-lenses, month-lenses or three-months'-lenses. Such lenses are a preferable embodiment of the current invention.
  • compositions to be used in the procedure according to the current invention are the following:

Abstract

A contact lens kit may include one or more soft contact lenses stored in an ophthalmologically acceptable solution of hyaluronic acid or a salt of hyaluronic acid. A method of disinfecting a soft contact lens, storing a soft contact lens, or facilitating insertion of a soft contact lens in an eye, may include placing the soft contact lens into an ophthalmologically acceptable solution that comprises (a) hyaluronic acid or a salt of hyaluronic acid, and (b) at least one compound to disinfect, store, or facilitate insertion of the contact lens.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application is a division of U.S. application Ser. No. 10/615,592, filed Jul. 8, 2003, now U.S. Pat. No. 7,569,212, which is incorporated herein by reference and which is a continuation of International Application No. PCT/NL02/00012, filed Jan. 9, 2002, which is incorporated herein by reference and which claims the benefit of Netherlands Application No. NL1017060, filed Jan. 9, 2001.
  • BACKGROUND
  • The current invention provides a procedure for the manufacture of contact lenses for eye treatment, eye protection and/or eye-care. The invention also provides a composition for the impregnation of a contact lens for the treatment and/or care and/or protection of the eye, a kit containing such a composition and one or more contact lenses as well as contact lenses impregnated with the composition.
  • Because they regularly have unusual objects in their eyes for years contact lens wearers have a higher chance of damaging their cornea, eye-stratum, the endothelium or other parts of the eyes than non-wearers, for example because chemical substances which may cause irritation or damage to the eye could be released from the lens or the surface of the lens after inserting the lens into the eyes. Lenses which have not been properly cleaned or damaged lenses as well as dust-particles, traces of sand or pollen which have gotten under the lens could also affect the cornea. These damages or irritations can be superficial and temporary, but could also result in far-reaching consequences since lenses are usually worn daily. Health risks could occur, varying from irritated and red eyes to serious complications such as permanent damage of the cornea resulting in blindness.
  • The cause of such complications is multifarious. Placing the contact lens onto the eye disturbs its physiological condition. After habituation a new balance will be reached that can be disturbed again by various factors, such as ageing of the contact lens, damage to and deposit on the lens, change of tear-flow with respect to composition and quantity due to frequency and manner of winking, chemical toxicity of substances the user is in contact with, mechanical pressure and chronic lack of oxygen. The ageing of the user may bring about changes in his or her eyes thereby disturbing the physiological balance. The use of medication or the development of allergies may also lead to irritations or damage of parts of the eyes.
  • Because nowadays contact lenses are frequently used for longer periods of time careful and regular cleaning has become more important. If this is not done sufficiently, bacteria, proteins etc., for instance, may cause irritations and damage more promptly. To prevent permanent damage it is vital that possible damage to the cornea or other parts of the eyes is treated as soon as possible.
  • Moreover, contact lens wearers may need extra protection for their eyes. It could be useful to the eyes to dispense extra nutrition, such as vitamins and provitamins or, additionally, those substances which offer protection or allow, support or accelerate the repair of an occurring damage. In eye healthcare several products are known to assist in the accelerated recovery of the soundness of the cornea. These products, however, usually have to be administered (dripped in or applied onto the eye) separately or have to be swallowed by the user.
  • SUMMARY
  • It is the aim of the current invention to provide the opportunity for a long-term care or treatment and/or protection and/or care of the eyes.
  • In accordance with one aspect of the present invention, a method for the production of contact lenses for the treatment and/or care and/or protection of the eye may comprise the impregnation of contact lenses in a solution which comprises one or more suitable components for the treatment and/or care and/or protection of the eye.
  • In accordance with another aspect of the present invention, a composition for the treatment and/or care and/or protection of the eye may comprise at least one suitable component for the treatment and/or care and/or protection of the eye.
  • In accordance with a further aspect of the present invention, a contact lens for treatment and/or care and/or protection of the eye may be impregnated with a composition comprising at least one suitable component for the treatment and/or care and/or protection of the eye.
  • DETAILED DESCRIPTION
  • Considering the possibilities of irritation and damage to the cornea, the stratum, the endothelium or other parts of the eyes are manifold, one requires protection, conditioning and whenever possible, restoration of the sustained damage to the eye. The current invention therefore provides a method for the manufacture of contact lenses for the treatment and/or care and/or protection of the eyes, comprising the impregnation of contact lenses in a solution which contains suitable compounds for the treatment and/or care and/or protection of the eyes. By wearing contact lenses the compounds which treat and/or protect and/or care of the eyes will be in contact with part of the eyes. This way the lens will be a method of administering these compounds which will often imply a more long-lasting administering compared to current eye-drops. The compounds mentioned can be either absorbed into the lens material or be attached to them or both. The term “impregnate” in this application refers to either of these or to a combination of both.
  • Furthermore the current invention provides a composition for the impregnation of contact lenses for the treatment and/or care and/or protection of the eyes, comprising compounds suitable for eye treatment or care or protection.
  • The current invention offers various types of compounds dependent on the type of treatment, care or protection required. For the benefit of the user these compositions can be combined with the compounds usually used for disinfecting, cleaning, insertion, moisturizing, rinsing or storing of contact lenses, so that the user need not add these compounds separately. However, it is likewise possible to just impregnate the lenses with the above-mentioned care or treatment products to prevent damage caused by other cleaning-agents or disinfectants.
  • Compounds that can be applied, but are not limited to substances which feed or treat the eye or may improve, accelerate or initiate local damage repair, or helps to avoid local damage or irritations of parts of the eye, are: for instance dexpanthenol, pantothenic acid, hyaluron acid, retinol (Vitamin A) and retinyl derivatives, carotene, thiamine (Vitamin B1), riboflavine (Vitamin B2), pyridoxine (Vitamin B6), nicotinic acid, nicotine acidamin, biotine (Vitamin B7), niacinamide and niacine (vitamin B3), ascorbic acid (Vitamin C) and other anti-oxidants, saccharose, honey and other bee products, red beetroot syrup, collagen, gelatin, taurin, serine protease and other enzymes, propamidines, Vitamin D and its derivatives such as calciferol, Vitamin K, tannin, pyruates, fibroplastin, fibronectine and fibrohydrolysate, heparin, alfa-ketaglutarine acid, carnisin, laminisin, mucin, tenascin, peptides epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and all ophthalmologically acceptable salts and derivatives of the compounds mentioned above, selenium, calcium, zinc and other minerals.
  • Products used for maintenance and storage of contact lenses, like cleaning products and disinfecting solutions, and sprays, so-called all-in-one solutions, storage liquids and rinsing liquids, insertion solutions and moisturizers, neutralizers in either liquid or tablet form, gels, coatings and tablets which either make or assist in making contact lens solutions or make solutions come into being or are used for or in such solutions.
  • According to the current invention the composition can therefore appear in various forms, such as a solution, spray or tablet which after dissolution makes a solution. Compounds intended for the care of contact lenses may also be part of a tablet which is combined with a solution that contains the care, treatment or protection agent or the reverse. Obviously both could also be included in one tablet or in separate tablets. Even so compounds can be included in a solution that is to be mixed with a solution without a compound.
  • Since the current substances which necessarily have to be applied for their germicidal and preservative effects in eye-care solutions, eye-drops and contact lens care solutions and which are germicidal in a short period of time and sufficiently limiting increase in germ population usually have the disadvantage of causing irritation or even attacking the eye to a large or lesser degree it would be greatly advantageous to use compounds in eyecare solutions, eye-drops and contact lens solutions for germicidal or conservation purposes which are non-irritant or protect against these irritations or damages. Possible damage and irritation of the cornea or other parts of the eye will thus be avoided. An additional aim of the current invention is to disclose a method for improvement of the way a desired (and often necessary) antibacterial effect of a composition for contact lens care or eye-care/eye-drops can be reached. A number of peptides are naturally found in the eye. They have a protective effect on the eye and particularly the cornea. The use of peptides in a composition for use in a contact lens solution, but also in eye-drops, could be greatly advantageous, because many peptides do not cause damage to the cornea; to some extent they also offer protection. They also offer protection from and support against bacterial infections, especially for people prone to such infections or people whose corneas are easily damaged.
  • According to the current invention peptides can be used separately or in combination with other eye-care products or treatments.
  • The composition according to the current invention can be applied when impregnating all kinds of contact lenses, especially and preferably soft lenses, but also hard lenses, disposable lenses and long-lasting ones as well as extended wear lenses and intra-ocular lenses would benefit. Impregnation can be carried out by the user, for instance during maintenance, but also, as with new lenses, in the delivery packaging.
  • It is not necessary for the user using the contact lenses according to the current invention to be already familiar with wearing lenses. People, and even animals, who in fact do not need any eye-correction, but who require for instance certain nutrients for the eye or products to possibly initiate, support or accelerate healing sores or injuries could wear contact lenses or similar objects according to the current invention on or in the eye to facilitate the required compound(s) on or into the eye. It is not necessary for the active component with which contact lenses have been impregnated to repair or prevent any damage. Also medicines can be administered through a contact lens according to the current invention. An example of another type of effective compound, in this case a medicine, which could be administered advantageously to the eye according to the current invention is for instance cromoglycate. This compound works as a precautionary protection against allergies. A contact lens with this compound could be used when the user expects an allergic reaction, for example in a period with high levels of pollen. Other compounds can be used as well to either prevent or reduce allergic reactions, such as emedastine, azelastine and nedocromil.
  • Other applications of contact lenses according to the current invention could be found in the treatment of so-called “dry eyes” or irritated or red eyes, hence called “dry eyes.” Currently mainly eye-drops are used to treat this. Such eye-drops, however, usually offer only short-term relief. In order to lengthen the availability of the active agents for the treatment of the eyes several complex or expensive possibilities for slow-release eye-drops have been proposed. The contact lenses according to the current invention offer a simple, cheap and elegant alternative.
  • It could be particularly advantageous to use the compounds suggested in the current invention as giving relief to dry eyes in combination with polymers from which is known or believed that they, when used in eye-drops, offer relief, such as polymers of the type polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), hydroxy propyl cellulose (HPC), Carbomere or Dextrane. Other substances that may be combined with the compounds include polyhexamethylene biguanide hydrochloride (PHMB HCl), boric acid, borax, sodium chloride (NaCl), and ethylenediamine tetraacetic acid (EDTA).
  • As mentioned above contact lenses according to the current invention can also be used to apply substances which cure or correct eye-diseases or disorders and which should be administered once or several times a day to take sufficient effect at least part of the day. The use of contact lenses according to the current invention could be effective here. Moreover, the use of contact lenses will generally result in a more constant level of the effective agent at the point of application than would have been possible with the use of eye-drops or even eye-balm. Eye-balm also has the disadvantages of causing limited eyesight directly after application and a less easy way of application for some users compared to applying contact lenses. For wearers of contact lenses the use of the current invention with their own lenses is particularly economical, because they do not need to perform any supplementary actions.
  • An advantage of the current invention is that the price of contact lenses has dropped considerably over the last few years especially that of short-term use lenses such as the so-called day-lenses, week-lenses, month-lenses or three-months'-lenses. Such lenses are a preferable embodiment of the current invention.
  • The current invention will be illustrated in the following examples:
  • EXAMPLES
  • Examples of compositions to be used in the procedure according to the current invention are the following:
  • A. All-In-One Solutions:
    • 1. PHMB HCl 2.5 ppm
    • 2. Boric Acid 0.75%
    • 3. Borax 0.15%
    • 4. NaCl 0.40%
    • 5. EDTA-Na 0.03%
    • 6. HPMC 10,000 0.10%
    • 7. Dexpanthenol 1.0%
    • 8. pH adaptation with NaOH or HCl to pH 7.4
    B. Neutralizers (Tablets):
    • 1. Catalase 3000 IU
    • 2. KH2PO4 50 mg
    • 3. K2hPO4 150 mg
    • 4. NaCl q.s.
    • 5. Na-EDTA 0.2 mg
    • 6. Collagene 5 mg
    • 7. PVP K 90 10 mg
    C. Storage Solutions and Insertion Solutions:
    • 1. HPMC 4000 cP 0.2%
    • 2. Citric Acid 0.5%
    • 3. Na citrate 1.0%
    • 4. NaCl to 300 mOsm
    • 5. Na-EDTA 0.02%
    • 6. Alexidine 2 HCL 0.5 ppm
    • 7. Hyaluronic Acid 0.25%
    • 8. pH adaptation with NaOH or HCL ad pH 7.2

Claims (20)

1. A contact lens kit comprising one or more soft contact lenses stored in an ophthalmologically acceptable solution of hyaluronic acid or a salt of hyaluronic acid.
2. The kit of claim 1, wherein the solution further comprises at least one compound to disinfect, store, or facilitate insertion of a soft contact lens into an eye.
3. The kit of claim 2, wherein the at least one compound comprises at least one of polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), hydroxy propyl cellulose (HPC), carbomere, and dextrane.
4. The kit of claim 1, wherein the one or more soft contact lenses are new lenses that are stored in the solution and packaged in delivery packaging.
5. The kit of claim 1, wherein the solution further comprises dexpanthenol.
6. The kit of claim 5, wherein the solution comprises at least 1% dexpanthenol by weight.
7. The kit of claim 5, wherein the soft contact lens is a day lens.
8. The kit of claim 5, wherein the solution is an all-in-one solution.
9. The kit of claim 1, wherein the soft contact lens is a day lens.
10. The kit of claim 1, wherein the solution is an all-in-one solution.
11. A method of disinfecting a soft contact lens, storing a soft contact lens, or facilitating insertion of a soft contact lens in an eye, comprising placing the soft contact lens into an ophthalmologically acceptable solution that comprises (a) hyaluronic acid or a salt of hyaluronic acid, and (b) at least one compound to disinfect, store, or facilitate insertion of the contact lens.
12. The method of claim 11 wherein the solution further comprises at least one of PVP, PVA, HPMC, HPC, carbomere, and dextrane.
13. The method of claim 11, wherein the solution comprises dexpanthenol.
14. The method of claim 13, wherein the solution comprises at least 1% dexpanthenol by weight.
15. The method of claim 13, wherein the soft contact lens is a day lens.
16. The method of claim 13, wherein the solution is an all-in-one solution.
17. The method of claim 11, wherein the soft contact lens is a day lens.
18. The method of claim 11, wherein the solution is an all-in-one solution.
19. The method of claim 11, wherein the soft contact lens is placed in the solution while the contact lens is not contacting an eye.
20. The method of claim 19, wherein the soft contact lens is a new lens and is in the solution while in delivery packaging.
US12/512,521 2001-01-09 2009-07-30 Soft contact lens solution containing hyaluronic acid Abandoned US20090291020A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/512,521 US20090291020A1 (en) 2001-01-09 2009-07-30 Soft contact lens solution containing hyaluronic acid

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL1017060 2001-01-09
NL1017060 2001-01-09
PCT/NL2002/000012 WO2002060495A1 (en) 2001-01-09 2002-01-09 Procedure and composition of treatment and/or care of the eye
US10/615,592 US7569212B2 (en) 2001-01-09 2003-07-08 Procedure and composition of treatment and/or care of the eye
US12/512,521 US20090291020A1 (en) 2001-01-09 2009-07-30 Soft contact lens solution containing hyaluronic acid

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/615,592 Division US7569212B2 (en) 2001-01-09 2003-07-08 Procedure and composition of treatment and/or care of the eye

Publications (1)

Publication Number Publication Date
US20090291020A1 true US20090291020A1 (en) 2009-11-26

Family

ID=19772702

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/615,592 Expired - Lifetime US7569212B2 (en) 2001-01-09 2003-07-08 Procedure and composition of treatment and/or care of the eye
US12/512,521 Abandoned US20090291020A1 (en) 2001-01-09 2009-07-30 Soft contact lens solution containing hyaluronic acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/615,592 Expired - Lifetime US7569212B2 (en) 2001-01-09 2003-07-08 Procedure and composition of treatment and/or care of the eye

Country Status (14)

Country Link
US (2) US7569212B2 (en)
EP (1) EP1347787B2 (en)
JP (1) JP2004521682A (en)
CN (1) CN1281283C (en)
AT (1) ATE292985T1 (en)
AU (1) AU2002228449B2 (en)
CA (1) CA2434242A1 (en)
DE (1) DE60203691T3 (en)
DK (1) DK1347787T4 (en)
ES (1) ES2240710T5 (en)
IL (2) IL156766A0 (en)
PL (1) PL198969B1 (en)
RU (1) RU2333742C2 (en)
WO (1) WO2002060495A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609957B (en) * 2016-06-27 2018-01-01 晶碩光學股份有限公司 Solution for treating contact lens and packaging system of contact lens

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
AU2002228449B2 (en) 2001-01-09 2007-12-06 Louis Johan Wagenaar Procedure and composition of treatment and/or care of the eye
MY128762A (en) * 2001-01-12 2007-02-28 Novartis Ag Lens care product containing dexpanthenol
DE10161110A1 (en) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmaceutical composition for ophthalmic and rhinological use
JP2006504701A (en) * 2002-09-30 2006-02-09 マーク・エー・バビザイェフ Method for local treatment of eye diseases, therapeutic composition and therapeutic means thereof
FR2849383B1 (en) * 2002-12-26 2005-09-30 Jean Noel Thorel TROPHIC COMPOSITION IN AQUEOUS MEDIUM, AND ITS APPLICATIONS, IN PARTICULAR IN OPHTHALMOLOGY
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
CA2839930C (en) * 2003-06-13 2016-07-05 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
JP4954076B2 (en) * 2004-10-01 2012-06-13 メニコン シンガポール ピーティーイー. リミテッド Contact lens packaging container solution
WO2006053164A2 (en) * 2004-11-09 2006-05-18 Advanced Medical Optics, Inc. Ophthalmic solution
US7726809B2 (en) 2005-02-09 2010-06-01 Safilens S.R.L. Contact lens, method for producing same, and pack for storage and maintenance of a contact lens
DE102005031361A1 (en) * 2005-06-30 2007-01-04 Biotronik Vi Patent Ag Use of propolis as a coating material for medical implants
DE102005055275A1 (en) 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphate-free pharmaceutical composition and its use
JPWO2007125731A1 (en) * 2006-04-28 2009-09-10 株式会社メニコン Soft contact lens solution, drug sustained release soft contact lens obtained using the same, and method for producing the same
ES2624960T3 (en) * 2006-09-29 2017-07-18 Johnson & Johnson Vision Care, Inc. Method of manufacturing ophthalmic devices used in the treatment of eye allergies
US20080166393A1 (en) * 2007-01-05 2008-07-10 Grant Robert K Eye Medication Delivery System
US20090081194A1 (en) * 2007-04-04 2009-03-26 Kalsow Carolyn M Compositions and methods for reducing risk of development, or severity, of inappropriate immune response in eyes
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
US20090142292A1 (en) * 2007-12-03 2009-06-04 Blackwell Richard I Method For The Mitigation of Symptoms of Dry Eye
US20110046033A1 (en) * 2008-01-31 2011-02-24 Jinzhong Zhang Multipurpose Lens Care Solution with Benefits to Corneal Epithelial Barrier Function
NL2002214C2 (en) * 2008-11-17 2010-05-18 Louis Johan Wagenaar Contact lens care solution.
WO2010092735A1 (en) 2009-02-10 2010-08-19 千寿製薬株式会社 Ring-shaped device
CA2753106C (en) * 2009-02-20 2016-09-13 Seed Co., Ltd. Hydrogel contact lens for sustained drug release and drug release method using hydrogel contact lens for sustained drug release
US8440212B2 (en) * 2009-08-24 2013-05-14 Arch Chemicals, Inc. Compositions for treating water systems
TW201206418A (en) * 2010-07-02 2012-02-16 Holden Brien Vision Inst Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
IT1407283B1 (en) * 2010-12-06 2014-04-04 Paoli Ambrosi De NEW COMPOUND OF CARNOSINE
CA2821969A1 (en) * 2010-12-21 2012-06-28 Recopharma Ab Tear substitutes
TWI480039B (en) * 2011-03-10 2015-04-11 Pegavision Corp Aqueous composition for contact lens
CN102600050B (en) * 2012-03-23 2013-05-08 上海暖友实业有限公司 Eye-protecting health care patch with self-heating steam and nutrition
PL2897604T3 (en) 2012-09-19 2018-10-31 Grespo Ab Compositions for improvement of brain function
CN105214071A (en) * 2015-05-28 2016-01-06 上海昊海生物科技股份有限公司 A kind of size variance eye drop and preparation method thereof
WO2017030184A1 (en) * 2015-08-20 2017-02-23 生化学工業株式会社 Agent to be applied to ophthalmic device
US9861940B2 (en) 2015-08-31 2018-01-09 Lg Baboh2O, Inc. Additives for salt rejection enhancement of a membrane
US11096391B1 (en) 2016-01-06 2021-08-24 Innovative Water Care, Llc Polybiguanide salts in solid form for water treatment applications and kit
US10155203B2 (en) 2016-03-03 2018-12-18 Lg Nanoh2O, Inc. Methods of enhancing water flux of a TFC membrane using oxidizing and reducing agents
TWI634205B (en) * 2016-06-27 2018-09-01 晶碩光學股份有限公司 Solution for treating contact lens
KR101932862B1 (en) 2017-10-30 2018-12-26 동국대학교 경주캠퍼스 산학협력단 Compositions for Preventing and Treating Dry Eye Syndrome
RU2679319C1 (en) * 2018-11-27 2019-02-07 Илья Александрович Марков Gel-like artificial tears with antiseptic and reparative action
KR102221500B1 (en) * 2019-06-10 2021-03-04 인제대학교 산학협력단 Method for manufacturing contact lens comprising beta-carotene for blocking blue lights
CN114191383A (en) * 2021-12-10 2022-03-18 江苏海伦隐形眼镜有限公司 Contact lens nutrient solution and using method thereof
CN114410391A (en) * 2022-01-26 2022-04-29 深圳中科欣扬生物科技有限公司 Contact lens care solution containing antioxidant substances and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039913A (en) * 1998-08-27 2000-03-21 Novartis Ag Process for the manufacture of an ophthalmic molding
US6082533A (en) * 1998-12-15 2000-07-04 Bausch & Lomb Incorporated Contact lens package
US6528048B1 (en) * 1998-11-16 2003-03-04 Rohto Pharmaceutical Co., Ltd. Ophthalmic solutions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426757A1 (en) * 1974-06-01 1975-12-11 Norbert Armin Guenther Contact lens made of hard or soft plastics - is impregnated with slow-release medicament for continuous eye treatment
SU1377104A1 (en) * 1985-07-19 1988-02-28 Куйбышевский медицинский институт им.Д.И.Ульянова Method of conducting photophoresis when curing eye diseases
US5091421A (en) * 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
JP3256997B2 (en) * 1990-08-30 2002-02-18 千寿製薬株式会社 Stable aqueous formulation
NZ242358A (en) * 1991-05-10 1994-03-25 Allergan Inc Use of thiol compounds to inhibit deposits on a contact lens
RU2055555C1 (en) * 1992-05-07 1996-03-10 Михаил Ефимович Маргус Device for curing eye diseases
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
JP4591728B2 (en) * 1998-12-28 2010-12-01 大正製薬株式会社 Eye drops for improving eye strain
ES2255987T3 (en) * 1999-03-01 2006-07-16 Milcin Therapeutics Llc OPHTHALMIC PREPARATIONS CONTAINING MUCINE.
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US8557868B2 (en) * 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
AU2002239545B2 (en) 2000-11-08 2006-10-05 Fxs Ventures, Llc Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
AU2002228449B2 (en) 2001-01-09 2007-12-06 Louis Johan Wagenaar Procedure and composition of treatment and/or care of the eye
MY128762A (en) * 2001-01-12 2007-02-28 Novartis Ag Lens care product containing dexpanthenol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039913A (en) * 1998-08-27 2000-03-21 Novartis Ag Process for the manufacture of an ophthalmic molding
US6528048B1 (en) * 1998-11-16 2003-03-04 Rohto Pharmaceutical Co., Ltd. Ophthalmic solutions
US6082533A (en) * 1998-12-15 2000-07-04 Bausch & Lomb Incorporated Contact lens package

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609957B (en) * 2016-06-27 2018-01-01 晶碩光學股份有限公司 Solution for treating contact lens and packaging system of contact lens
US10918761B2 (en) 2016-06-27 2021-02-16 Pegavision Corporation Solution for treating contact lens and contact lens packaging system

Also Published As

Publication number Publication date
AU2002228449B2 (en) 2007-12-06
ES2240710T5 (en) 2011-02-08
US20040057980A1 (en) 2004-03-25
CA2434242A1 (en) 2002-08-08
RU2003124644A (en) 2005-01-10
DE60203691T3 (en) 2011-08-18
CN1489480A (en) 2004-04-14
EP1347787B2 (en) 2010-09-08
DK1347787T3 (en) 2005-08-08
PL362746A1 (en) 2004-11-02
US7569212B2 (en) 2009-08-04
EP1347787B1 (en) 2005-04-13
PL198969B1 (en) 2008-08-29
IL156766A (en) 2009-05-04
CN1281283C (en) 2006-10-25
JP2004521682A (en) 2004-07-22
DE60203691D1 (en) 2005-05-19
WO2002060495A1 (en) 2002-08-08
EP1347787A1 (en) 2003-10-01
IL156766A0 (en) 2004-02-08
ATE292985T1 (en) 2005-04-15
RU2333742C2 (en) 2008-09-20
ES2240710T3 (en) 2005-10-16
DK1347787T4 (en) 2011-01-03
DE60203691T2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
US7569212B2 (en) Procedure and composition of treatment and/or care of the eye
AU2002228449A1 (en) Procedure and composition of treatment and/or care of the eye
ES2374607T3 (en) Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid.
US6024954A (en) Compositions and methods for disinfecting contact lenses and preserving contact lens care products
NL2002214C2 (en) Contact lens care solution.
JP2014028857A (en) Chlorous acid compound-containing aqueous composition containing menthol
KR100348237B1 (en) One-component combination preparation, disinfection, neutralization and cleaning methods for disinfecting, neutralizing and cleaning contact lenses
JP5686454B1 (en) Contact lens mounting liquid and method for improving refractive index of contact lens using the same
AU5454594A (en) Ophthalmic solution and method of use
JP6615548B2 (en) Ophthalmic composition
JP2009175731A (en) Chlorous acids compound-containing water-based composition containing glycerol and phosphoric acid compound
JP2009199074A (en) Aqueous composition containing chlorous acid compound containing polyoxyethylene castor oil derivative and phosphoric acid compound
EP1522321B1 (en) Method for disinfecting and/or cleaning contact lenses, using a liquid aqueous composition comprising at least one constituent of the aloe vera plant
JP4817621B2 (en) Contact lens care method and composition
JP2006000170A (en) Contact lens composition
JP2007513951A (en) Use of organic buffers to enhance the antimicrobial activity of pharmaceutical compositions
EP2642333B1 (en) Soft contact lens application method
Lyle et al. Constituents of Ophthalmic Preparations
JP2016183186A (en) Ophthalmic composition
WO2004082673A1 (en) Liquid ophthalmic composition

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION